FAP and sarcoma: 177Lu-FAP-2286 exhibited antitumor activity in FAP-expressing HEK293 tumors and sarcoma patient-derived xenografts, with no significant weight loss and longer tumor retention and suppression than treatment with radiolabeled FAPI-46 in animal studies [556].